数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Dementia is the leading cause of senile disability worldwide, currently affecting more than 50 million individuals, an estimate expected to triple by 2050, posing a significant challenge to global health [1].
方法
Peripheral blood samples from MCI (n = 11) and AD (n = 11) patients were collected at the Regional Neurogenetic Center (ASP CZ), Catanzaro.；Written informed consent was obtained from all participants for blood sample collection and the use of clinical data.；Clinical and family histories, neurological examinations, and neuropsychological tests were assessed for each patient [43,44,45].；Diagnoses were based on clinical and neuropsychological assessments; amyloid, tau, and neurodegeneration biomarkers (CSF or PET) were not available for any participant, and the cohorts were therefore not characterised with respect to underlying aetiology.
核心结论
结论：In conclusion, these findings identify miRNAs in L1CAM-enriched EVs as candidates for further investigation as minimally invasive markers in cognitive impairment.
局限
This study is cross-sectional, so group differences cannot establish within-individual change or progression between stages.；Future studies on glial-derived EVs may reveal additional key biomarkers.
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。最大样本量约 11；设计 Meta 分析、横断面。
全文来源
PMC JATS 全文（正文 40,131 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：L1CAM-Enriched Extracellular Vesicle MicroRNAs in Mild Cognitive Impairment and Alzheimer's Disease: An Exploratory Study.
- 期刊与标识：Int J Mol Sci · PMID 42942071 · DOI 10.3390/ijms27209301**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。